PMID- 29768347
OWN - NLM
STAT- MEDLINE
DCOM- 20180522
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 20
DP  - 2018 May
TI  - A retrospective study of alendronate for the treatment of ankylosing spondylitis.
PG  - e10738
LID - 10.1097/MD.0000000000010738 [doi]
LID - e10738
AB  - This retrospective study assessed the effect of alendronate for treating patients 
      with ankylosing spondylitis (AS).Eighty-six patients with AS were included in 
      this retrospective study, and were divided into 2 groups. Forty-six patients in 
      the intervention group received alendronate plus vitamin D (400 mg/day) and 
      calcium (500 mg/day), while 40 patients in the control group received vitamin D 
      and calcium only, the same dose as the intervention group. The primary outcome 
      included bone densitometry. The secondary outcomes consisted of quality of life, 
      measured by Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire, disease 
      activity, measured by Bath Ankylosing Spondylitis Disease Activity Index 
      (BASDAI), and functional status, measured by Bath Ankylosing Spondylitis 
      Functional Index (BASFI), as well as the adverse events (AEs).At the end of 
      6-month treatment, patients in the intervention group were not superior to the 
      patients in the control group in bone densitometry (hip, P = .47; lumbar, 
      P = .53), quality of life (P = .32), disease activity (P = .39), and functional 
      status (P = .41). Moreover, no significant differences in AEs were found between 
      2 groups.The results of the present study showed that alendronate can neither be 
      used to treat bone loss, nor to enhance the quality of life, disease activity, 
      and functional status.
FAU - Li, Gang
AU  - Li G
AD  - Department of Orthopedic Surgery Department of Critical-Care Medicine Department 
      of Anesthesia, The Affiliated Hongqi Hospital of Mudanjiang Medical University 
      Department of Anatomy, Mudanjiang Medical University, Mudanjiang, China.
FAU - Lv, Chang-An
AU  - Lv CA
FAU - Tian, Li
AU  - Tian L
FAU - Jin, Lian-Jin
AU  - Jin LJ
FAU - Zhao, Wei
AU  - Zhao W
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Bone Density Conservation Agents)
RN  - 1406-16-2 (Vitamin D)
RN  - SY7Q814VUP (Calcium)
RN  - X1J18R4W8P (Alendronate)
SB  - IM
MH  - Adult
MH  - *Alendronate/administration & dosage/adverse effects
MH  - Bone Density Conservation Agents/administration & dosage/adverse effects
MH  - *Calcium/administration & dosage/adverse effects
MH  - Densitometry/methods
MH  - Dose-Response Relationship, Drug
MH  - Drug Monitoring/methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain Measurement
MH  - Patient Acuity
MH  - Quality of Life
MH  - Retrospective Studies
MH  - Spondylitis, Ankylosing/diagnosis/*drug therapy/physiopathology/psychology
MH  - Treatment Outcome
MH  - *Vitamin D/administration & dosage/adverse effects
PMC - PMC5976316
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/05/17 06:00
MHDA- 2018/05/23 06:00
PMCR- 2018/05/18
CRDT- 2018/05/17 06:00
PHST- 2018/05/17 06:00 [entrez]
PHST- 2018/05/17 06:00 [pubmed]
PHST- 2018/05/23 06:00 [medline]
PHST- 2018/05/18 00:00 [pmc-release]
AID - 00005792-201805180-00027 [pii]
AID - MD-D-18-00941 [pii]
AID - 10.1097/MD.0000000000010738 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 May;97(20):e10738. doi: 10.1097/MD.0000000000010738.